Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ELDN)

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

GlobeNewswire 9 days ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

GlobeNewswire November 6, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 29, 2024

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

GlobeNewswire October 29, 2024

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 11, 2024

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

GlobeNewswire September 4, 2024

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

GlobeNewswire August 14, 2024

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

GlobeNewswire July 29, 2024

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

GlobeNewswire July 2, 2024
View More News ››

Opinion & Analysis (NDAQ:ELDN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELDN)

Eledon Pharmaceuticals Announces Positive Initial Data from

NEWS: $ELDN Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part...
whytestocks - October 29, 2024

Eledon Announces Clinical Progress with Tegoprubart in the P

News; $ELDN Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionFirst participant dosed in...
whytestocks - May 7, 2024

Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way i

NEWS: $ELDN Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage GainEledon Pharmaceuticals,...
whytestocks - April 22, 2024

ELDN - Thursday Rundown, Friday Expectations

<< View Post To Watch Video >>
HDavis - November 11, 2021

Is a Cure for Diabetes Being Studied

Is a Cure for Diabetes Enetering Phase II Trials? https://www.channelchek.com/news-channel/Is_a_Cure_for_Diabetes_Being_Studied_
SmallCapPaul - December 11, 2020

Functional Cure for T1D Discussion

Noble Capital Markets, Inc. Announces Type-1 Diabetes Day- The Beginning of the End; Close to a Cure?   A Panel of World...
SmallCapPaul - November 23, 2020
View more Bullboard ››

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical ...
View More »